High expression of the phosphoinositide
3-kinase p110γ isoform can predict poor prognosis of non-small cell lung cancer
Ina Jung1, Hyoun Wook Lee1, Mee Sook Roh2, Jae Seok Lee1, Kisu Kim1, Kyungeun Kim3, Tae Gyu Kim4 and Hyun-Yeol Nam5
1Department of Pathology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, 2Department of Pathology, Dong-A University College of Medicine, Busan, 3Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, 4Department of Radiation Oncology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine and 5Department of Nuclear Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, South Korea
Corresponding Author: Prof. Hyoun Wook Lee, Department of Pathology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, 158, Paryong-ro, Masanhoewon-gu, Changwon 51353, South Korea. e-mail: sudowo@naver.com
Summary. The protein p110γ is an isoform of the catalytic subunit of class I phosphoinositide 3-kinases (PI3Ks). PI3Ks are involved in the regulation of cell survival, growth, proliferation, and migration and have been implicated in the oncogenesis of various cancers. In this study, p110γ expression in non-small cell lung cancer (NSCLC) and its association with clinicopathological factors and patient survival were evaluated. A total of 230 NSCLC tumors were immunohistochemically stained for p110γ. Of these, 174 (75.7%) and 56 (24.3%) were placed in the low and high expression groups, respectively. The positive rate of p110γ was significantly higher in adenocarcinoma than in squamous cell carcinoma (p<0.001). Advanced stage NSCLCs showed higher p110γ expression than those at an early stage (p=0.002). Irrespective of the histological tumor type, the patients with high p110γ expression had significantly worse overall survival than those with low p110γ expression (p=0.004). p110γ expression was an independent poor prognostic factor in the multivariate analysis. Our results suggest that p110γ may be involved in the development and progression of NSCLC, and that p110γ has promising potential as a prognostic factor or novel therapeutic target for NSCLC. Histol Histopathol 37, 1177-1184 (2022)
Key words: Immunohistochemistry, Non-small cell lung cancer, PI3K, p110γ, Prognosis, Therapeutic target
DOI: 10.14670/HH-18-480
 |
©The Author(s) 2022. Open Access. This article is licensed under a Creative Commons CC-BY International License. |
